drugset / Trial / NCT01290575
Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.
Timeline
- Start
- 2011-02
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BMS-820132 | Unknown | 5 mg | Oral |
| Comparator | BMS-820132 | Unknown | 15 mg | Oral |
| Comparator | BMS-820132 | Unknown | 60 mg | Oral |
| Comparator | BMS-820132 | Unknown | 150 mg | Oral |
| Comparator | BMS-820132 | Unknown | 300 mg | Oral |
| Comparator | BMS-820132 | Unknown | 450 mg | Oral |